CTL epitopes from EBV

A cytotoxic T-cell epitope, the epitope being selected from the group consisting of YLLEMLWRL (SEQ ID NO:

• 1), YFLEILWGL (SEQ ID NO:
• 32), YLLEILWRL (SEQ ID NO:
• 33), YLQQNWWTL (SEQ ID NO:
• 6), LLLALLFWL (SEQ ID NO:
• 2), LLVDLLWLL (SEQ ID NO:
• 3), LLLIALWNL (SEQ ID NO:
• 4), WLLLFLAIL (SEQ ID NO:
• 5), TLLVDLLWL (SEQ ID NO:
• 7), LLWLLLFLA (SEQ ID NO:
• 8), ILLIIALYL (SEQ ID NO:
• 9), VLFIFGCLL (SEQ ID NO:
• 10), RLGATIWQL (SEQ ID NO:
• 11), ILYFIAFAL (SEQ ID NO:
• 15), SLVIVTTFV (SEQ ID NO:
• 17), LMIIPLINV (SEQ ID NO:
• 20), TLFIGSHVV (SEQ ID NO:
• 24), LIPETVPYI (SEQ ID NO:
• 26), VLQWASLAV (SEQ ID NO:
• 27) and QLTPHTKAV (SEQ ID NO:
• 29).

A subunit vaccine including at least one T-cell epitope selected from the group consisting of YLLEMLWRL (SEQ ID NO:

• 1), YFLEILWGL (SEQ ID NO:
• 32), YLLEILWRL (SEQ ID NO:
• 33), YLQQNWWTL (SEQ ID NO:
• 6), LLLALLFWL (SEQ ID NO:
• 2), LLVDLLWLL (SEQ ID NO:
• 3), LLLIALWNL (SEQ ID NO:
• 4), WLLLFLAIL (SEQ ID NO:
• 5), TLLVDLLWL (SEQ ID NO:
• 7), LLWLLLFLA (SEQ ID NO:
• 8), ILLIIALYL (SEQ ID NO:
• 9), VLFIFGCLL (SEQ ID NO:
• 10), RLGATIWQL (SEQ ID NO:
• 11), ILYFIAFAL (SEQ ID NO:
• 15), SLVIVTTFV (SEQ ID NO:
• 17), LMIIPLINV (SEQ ID NO:
• 20), TLFIGSHVV (SEQ ID NO:
• 24), LIPETVPYI (SEQ ID NO:
• 26), VLQWASLAV (SEQ ID NO:
• 27) and QLTPHTKAV (SEQ ID NO:
• 29).

An isolated nucleic acid sequence encoding at least one of the cytotoxic T-cell epitopes selected from the group consisting of YLLEMLWRL (SEQ ID NO:

• 1), YFLEILWGL (SEQ ID NO:
• 32), YLLEILWRL (SEQ ID NO:
• 33), YLQQNWWTL (SEQ ID NO:
• 6), LLLALLFWL (SEQ ID NO:
• 2), LLVDLLWLL (SEQ ID NO:
• 3), LLLIALWNL (SEQ ID NO:
• 4), WLLLFLAIL (SEQ ID NO:
• 5), TLLVDLLWL (SEQ ID NO:
• 7), LLWLLLFLA (SEQ ID NO:
• 8), ILLIIALYL (SEQ ID NO:
• 9), VLFIFGCLL (SEQ ID NO:
• 10), RLGATIWQL (SEQ ID NO:
• 11), ILYFIAFAL (SEQ ID NO:
• 15), SLVIVTTFV (SEQ ID NO:
• 17). LMIIPLINV (SEQ ID NO:
• 20), TLFIGSHVV (SEQ ID NO:
• 24), LIPETVPYI (SEQ ID NO:
• 26), VLQWASLAV (SEQ ID NO:
• 27) and QLTPHTKAV (SEQ ID NO:
• 29).

A method according to claim 27 wherein at least one CTL epitope selected from the group consisting of YLLEMLWRL (SEQ ID NO:

• 1), YFLEILWGL (SEQ ID NO:
• 32), YLLEILWRL (SEQ ID NO:
• 33), YLQQNWWTL (SEQ ID NO:
• 6), LLLALLFWL (SEQ ID NO:
• 2), LLVDLLWLL (SEQ ID NO:
• 3), LLLIALWNL (SEQ ID NO:
• 4), WLLLFLAIL (SEQ ID NO:
• 5), TLLVDLLWL (SEQ ID NO:
• 7), LLWLLLFLA (SEQ ID NO:
• 8), ILLIIALYL (SEQ ID NO:
• 9), VLFIFGCLL (SEQ ID NO:
• 10), RLGATIWQL (SEQ ID NO:
• 11), ILYFIAFAL (SEQ ID NO:
• 15), SLVIVTTFV (SEQ ID NO:
• 17), LMIIPLINV (SEQ ID NO:
• 20), TLFIGSHVV (SEQ ID NO:
• 24), LIPETVPYI (SEQ ID NO:
• 26), VLQWASLAV (SEQ ID NO:
• 27) and QLTPHTKAV (SEQ ID NO:
• 29), is administered to the subject.